Management

Walter V. Klemp

Walter V. Klemp

Chairman, President and Chief Executive Officer

Walter Klemp is a co-founder of Moleculin and has served as Chairman and CEO since July 2015 and as President since August 2017. He has founded and led four Nasdaq-listed companies across consumer products, dermatology, medical devices and oncology, with direct responsibility for more than $750 million in public and private financings. He also founded Autonomix Medical, Inc. (Nasdaq: AMIX), where he has served as Executive Chairman since January 2022. Mr. Klemp co-founded Soliton, Inc., a medical device company, and served as its CEO and later Executive Chairman from 2011 until its acquisition by AbbVie in December 2021 for approximately $550 million, following its 2018 Nasdaq IPO. He was previously President and CEO of Zeno Corporation (2003–2011), where he took a consumer medical device from concept through FDA clearance to national distribution, and founder, Chairman and CEO of Drypers Corporation (Nasdaq: DYPR) from 1987 to 2001, which grew to approximately $400 million in sales with operations in seven countries, ranked #1 on the Inc. 500 list of America’s fastest-growing private companies and became a Harvard Business School case study. He founded Moleculin’s predecessor, Moleculin, LLC, in 2007 to develop oncology drug candidates licensed from MD Anderson Cancer Center. He is a named inventor on more than a dozen issued US patents and received the American Marketing Association’s Gold Edison Award. Mr. Klemp earned a BA in Finance and Accounting from Lewis & Clark College and began his career at Coopers & Lybrand.

Jonathan P. Foster

Jonathan P. Foster

Executive VP & Chief Financial Officer

Jon Foster has served as Executive Vice President and Chief Financial Officer of Moleculin since August 2016, with responsibility for operations, finance, SEC reporting, capital markets and Nasdaq compliance. He brings more than 40 years of financial experience, including more than 20 years as CFO of public companies. Mr. Foster serves as a director of Autonomix Medical, Inc. (Nasdaq: AMIX), where he chairs the Audit and Compensation Committees, and of Empery Digital, Inc. (formerly Volcon, Inc.), where he chairs the Compensation Committee. From 2018 to 2021 he was a director of Soliton, Inc., chairing its Audit, Compensation and Strategic Committees through its Nasdaq IPO and its approximately $550 million acquisition by AbbVie. Before Moleculin, he was Executive Vice President and CFO of InfuSystem Holdings, Inc. (NYSE American: INFU) from 2012 to 2016 and, in the 1990s, Executive Vice President and CFO of Drypers Corporation during its growth into a Nasdaq-listed multinational. He began his career at Deloitte & Touche and served on the South Carolina Board of Financial Institutions from 2006 to 2012. Mr. Foster holds a BS in Accounting from Clemson University. He is a Certified Public Accountant (South Carolina) and a Chartered Global Management Accountant.

Donald Picker, PhD

Donald Picker, PhD

Chief Scientific Officer

Dr. Picker has served as our Chief Scientific Officer since August 2017 after serving as our Chief Operating Officer from July 2015 until August 2017 and as our president from January 2016 to August 2017. From 2006 through 2007, Dr. Picker was the President of Tapestry Pharmaceuticals. From 1998 to 2003, Dr. Picker was CEO of Synergy Pharmaceuticals. Synergy was merged into Callisto Pharmaceuticals where he was vice president of research and development until 2006. Dr. Picker led the development of carboplatin and cisplatin from concept to FDA approval. From 2018 to 2019, Dr. Picker served on the board of directors of CNS Pharmaceuticals, Inc., and Dr. Picker served as the Chief Science Officer of CNS Pharmaceuticals, Inc. on a part-time basis from 2018 until March 2026. Dr. Picker received his BS degree from Brooklyn Polytechnic University and his PhD from SUNY Albany in 1975. Dr. Picker is currently devoting only part of his work time to us and provides services as needed to us.

 John Paul Waymack, MD, ScD

John Paul Waymack, MD, ScD

Senior Chief Medical Officer

Paul Waymack is a former FDA medical officer and academic transplant surgeon with more than 30 years of drug-development leadership, including, as an FDA Medical Officer.  Among the drugs Dr. Waymack successfully developed was arsenic trioxide (Trisenox) for the indication of acute promyelocytic leukemia (APL). Dr. Waymack was the physician who identified the potential of this Chinese agent and convinced a U.S. VC firm to fund its development. He and others at the Hoyle firm then performed and supervised all the FDA regulatory, CMC, nonclinical and clinical work, which led to an NDA approval in approximately 3 years. It should be noted that APL is in the same family of hematological diseases as AML: the disease for which Annamycin is being developed. In 2013 Dr. Waymack co-founded Kitov Pharmaceuticals (Nasdaq and TASE: KTOV), serving as Chairman and Chief Medical Officer until 2019; during his tenure the company obtained FDA approval of its NDA for Consensi. For more than three decades he has advised Pfizer, Roche, Pharmacia, Warner-Lambert and Searle on regulatory strategy and clinical design as a drug-development consultant. Earlier he was Associate Professor of Surgery at the University of Texas Medical Branch and at the University of Medicine and Dentistry of New Jersey, where he directed the surgical intensive care unit, and served as a Major in the U.S. Army Medical Corps as Chief of Surgical Research at the Institute for Surgical Research. He has published more than 100 scientific papers and holds multiple patents. Dr. Waymack received his MD from the Virginia Commonwealth University School of Medicine and holds an ScD from the University of Cincinnati.

Robert Shepard, MD, FACP

Robert Shepard, MD, FACP

Medical Advisor

Dr. Shepard currently serves as a Medical Advisor to the Company. Prior to that, he served as our Chief Medical Officer, on a part-time basis, since June 2016. From 2013 until 2014, Dr. Shepard served as Vice President of Scientific and Medical Affairs for Accelovance. Dr. Shepard has extensive research credentials in hematology and oncology and is board certified in oncology, hematology and internal medicine. He has a wide array of experience in translational medicine and clinical research and has been actively involved in oncology research since 1970, responsible for the clinical development of several drugs and immune therapies for biopharmaceutical companies, including serving as the consulting Chief Medical Officer for six companies. Dr. Shepard is a Magna Cum Laude graduate of Harvard University in biochemical sciences and molecular biophysics and studied in the Harvard-M.I.T. Health Sciences program. He held fellowships in hematology and oncology at the Tufts-New England Medical Center where he conducted laboratory research in leukemias, myeloma and myelodysplasia, as well as fellowship in pharmacology and molecular genetics at the Dana-Farber Cancer Center and Harvard Medical School. Dr. Shepard holds academic appointments at Harvard University, Tufts University and the University of Virginia. Dr. Shepard is currently devoting only part of his work time to us and provides services as needed to us.

Board of Directors

Our Pipeline

Sign Up For Alerts